Bizarre Patents
A banana protective device for storing and transporting a banana carefully.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7399471 | Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient... | 07/15/2008 |
| 7364737 | Human neutralizing monoclonal antibodies to respiratory syncytial virus Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monocl... | 04/29/2008 |
| 7041292 | Treating prostate cancer with anti-ErbB2 antibodies The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies. ... | 05/09/2006 |
| 6949245 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies. ... | 09/27/2005 |
| 6793933 | Dietary supplements for enhancing the immune system Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to enhance the immune system (e.g., increase the activity of T and B lymphocytes and natural killer cells) in a mammal, said ability resultin... | 09/21/2004 |
| 6759055 | Dietary supplements for improving kidney function Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to improve kidney functions (e.g., restoring urine secretion and/or lowering blood urea nitrogen, serum proteinuria, and/or serum creatinine ... | 07/06/2004 |
| 6756050 | Dietary supplements for improving memory Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells have been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength for a period of time sufficient to increase the ca... | 06/29/2004 |
| 6753008 | Dietary supplements beneficial for the liver Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to normalize the serum level of GPT, AP and/or LDH-5 in a mammal, said ability resulting from their having been cultured in the presence of a... | 06/22/2004 |
| 6685942 | Human neutralizing monoclonal antibodies to respiratory syncytial virus A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup... | 02/03/2004 |
| 6682734 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 anti... | 01/27/2004 |
| 6509015 | Human antibodies that bind human TNFa Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. These antibodies have high affinity for hTNF (e.g., Kd =10-8 M or less), a s... | 01/21/2003 |
| 6491916 | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. These "humanized" anti-CD3 monoclonal antibodies retain, in vitro, all the properties of native anti-CD3 antibodies, inc... | 12/10/2002 |
| 6312690 | Monoclonal recombinant anti-rhesus D (D7C2) antibody Cloning of DNA fragments which code for the light chain or the heavy chain variable domain of the D7C2 monoclonal antibody within a baculovirus. The invention also concerns the expression of these DNA fragments in insect host cells, the anti-rhesus D reco... | 11/06/2001 |
| 5843439 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 anti... | 12/01/1998 |
| 5827534 | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery An oral dosage composition for intestinal delivery of a therapeutic agent comprising: (A) a therapeutic agent selected from the group consisting of a drug compound, a biologically active peptide and a vaccine; and (B) an intestinal absorption enhancing effecti... | 10/27/1998 |
| 5776456 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 anti... | 07/07/1998 |
| 5760185 | Anti-feline herpes virus-1 recombinant antibody and gene fragment coding for said antibody An anti-FHV-1 recombinant antibody efficacious for treatment, prevention and diagnosis of feline herpes virus-1 (FHV-1) and a gene fragment useful for preparing the same are provided. A cell producing a mouse monoclonal antibody having an excellent neutra... | 06/02/1998 |
| 5736137 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 anti... | 04/07/1998 |
| 5653980 | Vaccine comprising part of constant region of IgE for treatment of IgE-mediated allergic reactions The invention relates to a vaccine, preferably for human use, against IgE-mediated allergic reactions. The vaccine contains a protein having the entire amino acid sequence of the constant CH2-CH3 domains of the epsilon chain of the IgE molecule or a struc... | 08/05/1997 |
| 5314995 | Therapeutic interleukin-2-antibody based fusion proteins The present invention relates to antibody-based fusion proteins wherein a portion of an immunoglobulin molecule is linked to a biologically active ligand. In particular embodiments of the invention, the fusion protein comprises a portion of an antibody wh... | 05/24/1994 |
| 5258498 | Polypeptide linkers for production of biosynthetic proteins Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves a... | 11/02/1993 |
| 5225539 | Recombinant altered antibodies and methods of making altered antibodies An altered antibody is produced by replacing the complementarity determining regions (CDRs) of a variable region of an immunoglobulin (Ig) with the CDRs from an Ig of different specificity, using recombinant DNA techniques. The gene coding sequences for p... | 07/06/1993 |
| 5132405 | Biosynthetic antibody binding sites Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences The United States government has rights in this invention pursuant to small business innovation research grant ... | 07/21/1992 |
